| P50 | author | Bi Rong Dong | Q87466239 |
| | Taixiang Wu | Q67189809 |
| P2093 | author name string | Guan J Liu | |
| | Jirong Yue | |
| | Qiukui Hao | |
| P2860 | cites work | Treatment of pulmonary embolism with urokinase. Results of clinical trial (phase 1) | Q71623714 |
| | Comparison of Streptokinase and Heparin in Treatment of Isolated Acute Massive Pulmonary Embolism | Q71786257 |
| | Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group | Q72179442 |
| | Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion | Q72211275 |
| | Urokinase in Pulmonary Embolism | Q72309501 |
| | Urokinase therapy in clinical pulmonary embolism. A new thrombolytic agent | Q72309504 |
| | Resolution of pulmonary embolism: effect of therapy and putative age of emboli | Q73098171 |
| | Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group | Q73451510 |
| | Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up | Q74485252 |
| | Comparison of alteplase versus heparin for resolution of major pulmonary embolism | Q77483733 |
| | Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism | Q77933829 |
| | Thrombolysis for pulmonary embolism | Q78358747 |
| | Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism | Q80809293 |
| | The ATTRACT trial: rationale for early intervention for iliofemoral DVT | Q82390311 |
| | Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Throm | Q82976078 |
| | Management of unsuccessful thrombolysis in acute massive pulmonary embolism | Q83143074 |
| | Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism | Q84733867 |
| | Thrombolytic therapy for pulmonary embolism | Q24239835 |
| | Thrombolytic therapy for pulmonary embolism | Q24246260 |
| | Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial | Q33590122 |
| | Streptokinase and Heparin versus Heparin Alone in Massive Pulmonary Embolism: A Randomized Controlled Trial. | Q33884490 |
| | Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction | Q34064989 |
| | Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association | Q34172244 |
| | Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a meta-analysis | Q34420057 |
| | Systematic review and meta-analysis for thrombolysis treatment in patients with acute submassive pulmonary embolism | Q35115224 |
| | Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis | Q35189903 |
| | Management dilemmas in acute pulmonary embolism | Q37552634 |
| | Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. | Q38219389 |
| | Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial | Q38379116 |
| | Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism | Q38441382 |
| | Bolus injection of thrombolytic agents during cardiopulmonary resuscitation for massive pulmonary embolism | Q40562009 |
| | The role of recombinant human tissue-type plasminogen activator in the treatment of acute pulmonary thromboembolism | Q41832972 |
| | PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. | Q43604229 |
| | Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. | Q43696881 |
| | Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial | Q43784275 |
| | Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism | Q43792422 |
| | Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. | Q43802931 |
| | Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism | Q44175857 |
| | A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism | Q45021481 |
| | Fibrinolysis for patients with intermediate-risk pulmonary embolism | Q45144900 |
| | Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). | Q45912871 |
| | Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism | Q46985195 |
| | Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial | Q48087063 |
| | Urokinase therapy in pulmonary thromboembolism | Q49132023 |
| | Recombinant tissue plasminogen activator for hemodynamically stable patients experiencing an acute pulmonary embolism: a meta-analysis. | Q51723952 |
| | Desmoteplase in acute massive pulmonary thromboembolism. | Q51774056 |
| | Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. | Q54195441 |
| | Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. | Q54276013 |
| | The urokinase-streptokinase pulmonary embolism trial (phase II) results. | Q54632732 |
| | Thrombolytic Therapy: Differences Between Streptokinase and Urokinase | Q67232855 |
| | Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators | Q67273191 |
| | The urokinase pulmonary embolism trial | Q69303633 |
| | Comparison by Controlled Clinical Trial of Streptokinase and Heparin in Treatment of Life-threatening Pulmonary Embolism | Q69335295 |
| | Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism | Q69921554 |
| | Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial | Q70261989 |
| | Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism | Q70373273 |
| | Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism | Q71310468 |
| P921 | main subject | thrombolysis | Q1931577 |
| P577 | publication date | 2015-09-30 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Thrombolytic therapy for pulmonary embolism | |